<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00202280</url>
  </required_header>
  <id_info>
    <org_study_id>BPREC 26/2004</org_study_id>
    <secondary_id>03T-472</secondary_id>
    <nct_id>NCT00202280</nct_id>
  </id_info>
  <brief_title>Efficacy of Treating First Episode Psychosis With Folic Acid,B12 and B6 in Addition to Antipsychotic Medication</brief_title>
  <official_title>VIP (Vitamins In Psychosis) Study. A Randomized Double Blind Placebo Controlled Trial of the Effects of Vitamin B12, B6 and Folic Acid Augmentation on Cognition and Symptoms in Early Psychosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Melbourne Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanley Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Melbourne Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Vitamin B12,B6 and Folic Acid are effective&#xD;
      with antipsychotic medication in the treatment of First Episode Psychosis.The B-complex&#xD;
      Vitamins' homocysteine lowering properties may have an effect on cognition and symptoms. We&#xD;
      are examining changes in symptoms and cognition over a 3 month period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The core rationale of this study will be to prospectively investigate whether Vitamin B12, B6&#xD;
      and Folic Acid and the associated lowering of homocysteine levels will improve and /or&#xD;
      protect cognitive functioning in a cohort of 120 first episode psychosis patients.&#xD;
&#xD;
      This is a randomized, double blind placebo controlled add on standard therapy trial with&#xD;
      vitamin B12, B6 and folic acid, in young patients between 15-25 presenting to ORYGEN Youth&#xD;
      Health with a first psychotic episode . Vitamins (B12 , B6 and Folate) will be compared with&#xD;
      placebo added to standard treatment for a period of 12 weeks in a double blind fashion.&#xD;
      Primary outcome measures will be psychopathology and cognition (CogState and MATRICS).&#xD;
      Secondary outcome measures will be tolerability and safety measures (drop-out rates, general&#xD;
      side effect scale (UKU).&#xD;
&#xD;
      Patients who give informed consent will be randomised to receive treatment with vitamin (5 mg&#xD;
      folic acid, 0.4 mg B12, and 50 mg B6) daily or placebo for 12 weeks.&#xD;
&#xD;
      Patients will be randomised by a dynamic randomisation method called minimization which&#xD;
      allocates patients to treatment group by checking the allocation of similar patients already&#xD;
      randomised, and allocating the next treatment group &quot;live&quot; to best balance the treatment&#xD;
      groups across all stratification variables. The minimization will be carried out by the NHMRC&#xD;
      clinical trials centre in Sydney , and the patient will be randomized to either placebo or&#xD;
      vitamin. Each patient will collect their tablets from the clinical trials pharmacy. The&#xD;
      Clinical Trials Pharmacy will dispense either vitamin or placebo. All study personnel and&#xD;
      participants will be blinded to treatment assignment for the duration of the study. To&#xD;
      enhance the quality of measurement (and increase the power of the study by avoiding dilution&#xD;
      of effect) adherence to medication will be measured electronically with electronic pill caps&#xD;
      (Medication Event Monitoring System VI, ARRDEX Ltd). This will allow us to assess actual&#xD;
      pharmacological exposure in an objective manner.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognition (MATRICS and COGSTATE)at 3 months</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptomatology at 3 months</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety at 3 months</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability at 3 months</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>First Episode Psychosis</condition>
  <arm_group>
    <arm_group_label>Placebo pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pill daily for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5mg folic acid, 0.4mg B12, 50mg B6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5mg folic acid, 0.4mg B12, 50mg B6 in one pill, daily for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folic Acid 5mg, Vitamin B12 0.4mg and B6 50mg</intervention_name>
    <arm_group_label>5mg folic acid, 0.4mg B12, 50mg B6</arm_group_label>
    <arm_group_label>Placebo pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and females&#xD;
&#xD;
          -  Between 15 and 25 years of age&#xD;
&#xD;
          -  First Episode Psychosis&#xD;
&#xD;
          -  3 months of treatment&#xD;
&#xD;
          -  Attending ORYGEN Youth Health, a geographical based catchment area service for young&#xD;
             people aged between 15 and 25&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Untreated B12 deficiency or untreated pernicious anaemia&#xD;
&#xD;
          -  Patients on multi-vitamins, single B6, or folic acid, unless willing to discontinue&#xD;
             and take study supplement&#xD;
&#xD;
          -  Chronic haemolytic states such as thalassaemia major or sickle-cell anaemia&#xD;
&#xD;
          -  Hypersensitivity to folic acid&#xD;
&#xD;
          -  Organic disorders presenting with a psychotic syndrome (e.g. brain tumour, temporal&#xD;
             lobe epilepsy, HIV encephalopathy)&#xD;
&#xD;
          -  Mental retardation (unable and/or unlikely to give appropriate information of&#xD;
             symptomatology or side-effects (IQ approximately lower than 70)&#xD;
&#xD;
          -  History of clinically significant physical illness (e.g. terminal cancer, renal&#xD;
             dialysis)&#xD;
&#xD;
          -  History of brain surgery&#xD;
&#xD;
          -  History of brain infarction&#xD;
&#xD;
          -  Pregnant or lactating women, or women of childbearing potential not using an&#xD;
             acceptable method of contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Colin P O'Donnell, MB,MRCPsych</last_name>
    <role>Principal Investigator</role>
    <affiliation>ORYGEN Research Centre , ORYGEN Youth Health,Department of Psychiatry, University of Melbourne</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prof Patrick D McGorry, PhD FRANZP</last_name>
    <role>Study Director</role>
    <affiliation>ORYGEN Research Centre , ORYGEN Youth Health,Department of Psychiatry, University of Melbourne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ORYGEN Youth Health</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>September 14, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>November 18, 2015</last_update_submitted>
  <last_update_submitted_qc>November 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B 12</mesh_term>
    <mesh_term>Hydroxocobalamin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>March 25, 2019</submitted>
    <returned>June 19, 2019</returned>
    <submitted>August 22, 2019</submitted>
    <submission_canceled>August 23, 2019</submission_canceled>
    <submitted>August 23, 2019</submitted>
    <returned>September 24, 2019</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

